Diagnostic screening programs help catch cancer, abnormalities or other diseases before they reach an advanced stage, saving lives and healthcare costs. Screening programs include, lung, breast, prostate, and cervical cancer, among many others.
CT calcium scoring provides valuable evaluations of intermediate-risk patients in addition to making good business sense for hospitals. Nauman Mushtaq, MD, an interventional cardiologist with Northwestern, shared his own experience with this technology.
Since being approved by the U.S. Food and Drug Administration in 2011, DBT has become the most common method for breast cancer screening, and as of September 2022, 84% of all U.S. mammography screening facilities housed DBT units.
A team of experts with the University of Maryland School of Medicine recently presented ChatGPT with a set of questions relative to breast cancer screening recommendations to determine whether the program could reliably offer appropriate guidance.
Accurate information relative to personal risk is crucial for improving uptake of low-dose CT (LDCT) lung cancer screening, but new data indicate that many websites' content on the topic is out of date.
How recent developments in hormonal contraceptives affect breast density is an important consideration, as an increase in density category increases cancer risk.
Prior research has shown that not only is contrast-enhanced spectral mammography comparable to CE-MRI in accuracy of loco-regional staging, but some studies have even found it to perform better.
Using risk model-based strategies to determine who should undergo low-dose CT lung cancer screening is more cost effective than current U.S. Preventive Services Task Force guidelines.
The FDA-approved technology developed by HeartFlow can predict a patient's long-term risk of target vessel failure as well as more invasive treatments performed inside a cath lab.